Accumulation of senescent cells in various tissues has been reported to have a pathological role in age-associated diseases.
Publications
Positive FDA Feedback Supports BLA Submission for Lifileucel in Melanoma
The FDA has provided positive feedback regarding Iovance Biotherapeutics, Inc.’s proposed matrix of potency assays for an upcoming biologics license application (BLA) seeking the approval of lifileucel (LN-144) in the treatment of patients with metastatic melanoma.
Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study
Immunotherapy revolutionized cancer care in the last decade and, notably among its tools, the programmed cell death protein-1 (PD-1) inhibitors.
Second-Line Treatment With Apatinib in Patients with Recurrent or Refractory Melanoma
According to Shumin Yuan and colleagues from the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital in Zhengzhou, China, metastatic malignant melanoma is associated with very poor prognosis, partly due to resistance against conventional chemotherapies.